Navigation Links
Experimental treatment offers relief from painful prostate condition
Date:5/17/2011

New findings show that treatment with a specific alpha blocker helps reduce symptoms and improve quality of life for men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

The alpha-blocker, known as silodosin, works by selectively relaxing the muscles in the bladder neck and prostate. The treatment is already approved in Canada, the United States, the EU and Japan to treat painful symptoms of another prostate gland condition, benign prostatic hyperplasia, commonly referred to as an enlarged prostate.

Despite being the most common form of prostatitis, CP/CPPS is the most misunderstood and difficult to treat because the symptoms are very similar to other conditions and requires a significant degree of testing and screening to identify.

"Antibiotics are commonly used as a treatment, but are not typically effective, probably because CP/CPPS does not seem to be caused by a bacterial infection," explains lead researcher Curtis Nickel, a professor in the Department of Urology, practicing urologist at Kingston General Hospital, and Canada Research Chair in Urologic Pain and Inflammation.

CP/CPPS is a debilitating condition characterized by persistent discomfort in the lower pelvic area including the bladder area, testicles, and penis. Symptoms can be severe and include painful and frequent urination and difficult or painful ejaculation. The cause of the condition is unknown.

In Dr. Nickel's study, approximately 60 per cent of men reported feeling better after treatment with silodosin versus 30 per cent of participants who were given a placebo. The number of patients who reported feeling better is higher than in a similar study he ran several years ago that tested the effects of a different alpha blocker.

Dr. Nickel, along with his Prostatitis Research Group at Kingston General Hospital and Queen's University, has been studying CP/CPPS for the past two decades. He has been the principal investigator of over a dozen international clinical trials evaluating therapies for chronic prostatitis. His research studies are supported by the Canadian Institute of Health Research, US National Institutes of Health and industry, including Watson Pharmaceuticals who provided the support for this particular clinical trial.


'/>"/>

Contact: Christina Archibald
christina.archibald@queensu.ca
613-533-2877
Queen's University
Source:Eurekalert  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental treatment offers relief from painful prostate condition
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke ... young adults, has kicked off its 4th annual Forum for Innovative Treatment Solutions ... is “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 ...
(Date:4/21/2017)... ... 2017 , ... The adage “Show, don’t tell” applies perfectly to Green Builder ... esteemed VISION House demonstration project series. Manifesting the concept of right-sized living, the Flex ... to live affordably and abundantly without unduly taxing the resources of our beautiful planet. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... with O2X , an active lifestyle company that provides Human Performance Training ... of firefighters, police offers, first responders, military officers and others in service through ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... held the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 ... local medical community, offering physicians and healthcare providers an opportunity to learn about ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
Breaking Medicine Technology: